Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (326)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Seribantumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Seribantumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Istiratumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Istiratumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Dalotuzumab (Ref)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Dalotuzumab (Ref) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
MEDI3617 (Anti-Ang2)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule MEDI3617 (Anti-Ang2) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trebananib	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Trebananib Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vanucizumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vanucizumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Navicixizumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Navicixizumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Enavatuzumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Enavatuzumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tarextumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Tarextumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Rovalpituzumab (Ref)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Rovalpituzumab (Ref) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Anetumab Ravtansine	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Anetumab Ravtansine Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Sacituzumab Tirumotecan	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Sacituzumab Tirumotecan Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

Seribantumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Istiratumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Dalotuzumab (Ref) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
MEDI3617 (Anti-Ang2) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trebananib Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vanucizumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Navicixizumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Enavatuzumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tarextumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Rovalpituzumab (Ref) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Anetumab Ravtansine Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Sacituzumab Tirumotecan Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

‹ 1 … 21 22 23 24 25 … 28 ›

Product Range

Company

Global Network

Products

Seribantumab

Istiratumab

Dalotuzumab (Ref)

MEDI3617 (Anti-Ang2)

Trebananib

Vanucizumab

Navicixizumab

Enavatuzumab

Tarextumab

Rovalpituzumab (Ref)

Anetumab Ravtansine

Sacituzumab Tirumotecan

Seribantumab

Istiratumab

Dalotuzumab (Ref)

MEDI3617 (Anti-Ang2)

Trebananib

Vanucizumab

Navicixizumab

Enavatuzumab

Tarextumab

Rovalpituzumab (Ref)

Anetumab Ravtansine

Sacituzumab Tirumotecan